[ET Net News Agency, 20 May 2020] CSPC Pharmaceutical Group Limited (01093) said
"Docetaxel for Injection (albumin-bound)" developed by CSPC Zhongqi Pharmaceutical
Technology (Shijiazhuang) Co., Ltd., a subsidiary of the company, has obtained an appoval
granted by the National Medical Products Administration of the People's Republic of China
to conduct clinical trials in China.
The product applies innovative technology to encapsulate docetaxel into human serum
albumin and is planned to develop for solid tumour indication. (RC)